Rigel Pharmaceuticals (RIGL) EBIAT: 2010-2025
Historic EBIAT for Rigel Pharmaceuticals (RIGL) over the last 14 years, with Sep 2025 value amounting to $27.9 million.
- Rigel Pharmaceuticals' EBIAT rose 124.62% to $27.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $113.3 million, marking a year-over-year increase of 2819.35%. This contributed to the annual value of $17.5 million for FY2024, which is 169.69% up from last year.
- As of Q3 2025, Rigel Pharmaceuticals' EBIAT stood at $27.9 million, which was down 53.20% from $59.6 million recorded in Q2 2025.
- Rigel Pharmaceuticals' EBIAT's 5-year high stood at $59.6 million during Q2 2025, with a 5-year trough of -$27.4 million in Q1 2022.
- For the 3-year period, Rigel Pharmaceuticals' EBIAT averaged around $8.3 million, with its median value being $737,000 (2023).
- Per our database at Business Quant, Rigel Pharmaceuticals' EBIAT plummeted by 169.48% in 2022 and then soared by 5,887.67% in 2025.
- Rigel Pharmaceuticals' EBIAT (Quarterly) stood at -$22.6 million in 2021, then surged by 106.19% to $1.4 million in 2022, then crashed by 47.39% to $737,000 in 2023, then skyrocketed by 1,845.86% to $14.3 million in 2024, then surged by 124.62% to $27.9 million in 2025.
- Its EBIAT stands at $27.9 million for Q3 2025, versus $59.6 million for Q2 2025 and $11.4 million for Q1 2025.